巴瑞替尼在皮肤科的临床应用进展

doi:10.35541/cjd.20230528

Abstract

Abstract: 【Abstract】 Baricitinib, as a Janus kinase （JAK）1/JAK2 inhibitor, is primarily used for immunoinflammatory diseases such as rheumatoid arthritis. However, it has certain therapeutic potential in the field of dermatology and has shown promising efficacy in clinical trials. This review summarizes the application of baricitinib in the treatment of skin diseases in recent years, aiming to provide more comprehensive clinical medication guidance for clinicians.

Key words: Janus kinase inhibitors, Baricitinib, Inflammation, Autoimmunity, Skin diseases, Clinical application DOI: 10.35541/cjd.20230528

Gao Jinping, Zhang Xuejun, . Clinical application of baricitinib in dermatology[J]. Chinese Journal of Dermatology,2024,e20230528. doi:10.35541/cjd.20230528

References ［43］

［1］	Banerjee S, Biehl A, Gadina M, et al. JAK⁃STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects［J］. Drugs, 2017,77（5）:521⁃546. doi: 10.1007/s40265⁃017⁃0701⁃9.
［2］	King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study［J］. J Am Acad Dermatol, 2021,85（4）:847⁃853. doi: 10. 1016/j.jaad.2021.05.050.
［3］	King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata［J］. N Engl J Med, 2022,386（18）:1687⁃1699. doi: 10.1056/NEJMoa2110343.
［4］	Gupta AK, Wang T, Vincent K, et al. Olumiant® （Baricitinib）⁃a newly approved janus kinase inhibitor for the treatment of alopecia areata［J］. Skinmed, 2022,20（6）:452⁃455.
［5］	Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phaseⅢ trials （BRAVE⁃AA1 and BRAVE⁃AA2）［J］. Am J Clin Dermatol, 2023,24（3）:443⁃451. doi: 10.1007/s40257⁃023⁃00764⁃w.
［6］	Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment of atopic dermatitis［J］. J Dermatolog Treat, 2022,33（5）:2404⁃2413. doi: 10.1080/09546634.2021.1967268.
［7］	Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: patient⁃reported outcomes from two randomized monotherapy phaseⅢtrials［J］. J Dermatolog Treat, 2022,33（3）:1521⁃1530. doi: 10. 1080/09546634.2020.1839008.
［8］	Silverberg JI, Simpson EL, Wollenberg A, et al. Long⁃term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials［J］. JAMA Dermatol, 2021,157（6）:691⁃699. doi: 10.1001/jamadermatol. 2021.1273.
［9］	Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five PhaseⅢ clinical trials［J］. Eur J Dermatol, 2022,32（4）:522⁃529. doi: 10.1684/ejd.2022.4280.
［10］	Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate⁃to⁃severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo⁃controlled, phaseⅢ clinical trial （BREEZE⁃AD4）［J］. Br J Dermatol, 2022,187（3）:338⁃352. doi: 10.1111/bjd.21630.
［11］	Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate⁃to⁃severe atopic dermatitis from the BREEZE⁃AD7 phase 3 randomized trial［J］. J Eur Acad Dermatol Venereol, 2021,35（7）:1543⁃1552. doi: 10.1111/jdv.17278.
［12］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［13］	Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: from rheumatoid arthritis to COVID⁃19［J］. J Clin Pharmacol, 2021,61（10）:1274⁃1285. doi: 10.1002/jcph.1874.
［14］	Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10143）:222⁃231. doi: 10.1016/S0140⁃6736（18）31363⁃1.
［15］	Dörner T, van Vollenhoven RF, Doria A, et al. Baricitinib decreases anti⁃dsDNA in patients with systemic lupus erythematosus: results from a phaseⅡ double⁃blind, randomized, placebo⁃controlled trial［J］. Arthritis Res Ther, 2022,24（1）:112. doi: 10.1186/s13075⁃022⁃02794⁃x.
［16］	Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 3 trial （SLE⁃BRAVE⁃Ⅰ）［J］. Lancet, 2023,401（10381）:1001⁃1010. doi: 10.1016/S0140⁃6736（22）02607⁃1.
［17］	Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 3 trial （SLE⁃BRAVE⁃Ⅱ）［J］. Lancet, 2023,401（10381）:1011⁃1019. doi: 10.1016/S0140⁃6736（22）02546⁃6.
［18］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［19］	Dong J, Huang X, Ma LP, et al. Baricitinib is effective in treating progressing vitiligo in vivo and in vitro［J］. Dose Response, 2022,20（2）:155932582 21105370. doi: 10.1177/15593258221105370.
［20］	Li X, Sun Y, Du J, et al. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB⁃UVB phototherapy［J］. Clin Cosmet Investig Dermatol, 2023,16:635⁃638. doi: 10. 2147/CCID.S396430.
［21］	Hou Z, Su X, Han G, et al. JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis［J］. Front Med （Lausanne）, 2022,9:859330. doi: 10.3389/fmed.2022.859330.
［22］	Fujita Y, Nawata M, Nagayasu A, et al. Fifty⁃two⁃week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease⁃modifying antirheumatic drug therapy that was successfully treated with baricitinib: a novel case report［J］. Case Rep Rheumatol, 2019,2019:5293981. doi: 10.1155/2019/5293981.
［23］	Boleto G, Cren JB, Avouac J, et al. Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis⁃rheumatoid arthritis overlap syndrome［J］. Clin Exp Rheumatol, 2021,39 Suppl 131（4）:163⁃164. doi: 10.55563/clinexprheumatol/gu1ac8.
［24］	Salz M, Haeberle S, Hoffmann J, et al. Elevated IL⁃31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180⁃IgE［J］. J Dermatol Sci, 2017,87（3）:309⁃311. doi: 10.1016/j.jdermsci.2017.07.019.
［25］	Cornelissen C, Lüscher⁃Firzlaff J, Baron JM, et al. Signaling by IL⁃31 and functional consequences［J］. Eur J Cell Biol, 2012,91（6⁃7）:552⁃566. doi: 10.1016/j.ejcb.2011.07.006.
［26］	Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib［J］. Dermatol Ther, 2022,35（10）:e15754. doi:10. 1111/dth.15754.
［27］	You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases［J］. Clin Rev Allergy Immunol, 2020,59（3）:334⁃351. doi: 10.1007/s12016⁃020⁃08786⁃6.
［28］	Kim H, Dill S, O'Brien M, et al. Janus kinase （JAK） inhibition with baricitinib in refractory juvenile dermatomyositis［J］. Ann Rheum Dis, 2021,80（3）:406⁃408. doi: 10.1136/annrheumdis⁃2020⁃218690.
［29］	Zhao Q, Zhu Z, Fu Q, et al. Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open⁃label study［J］. J Am Acad Dermatol, 2022,87（6）:1374⁃1376. doi: 10.1016/j.jaad. 2022.08.025.
［30］	Landon⁃Cardinal O, Guillaume⁃Jugnot P, Toquet S, et al. JAK inhibitors for the treatment of adult dermatomyositis: a pilot study［J］. J Am Acad Dermatol, 2023,88（4）:924⁃926. doi: 10.1016/j.jaad.2022.10.055.
［31］	Wang Z, Zheng Q, Xuan W, et al. Short⁃term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis［J］. Front Pediatr, 2022,10:962585. doi: 10. 3389/fped.2022.962585.
［32］	Mastrolia MV, Orsini SI, Marrani E, et al. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis［J］. Clin Exp Rheumatol, 2023,41（2）:402⁃403. doi: 10.55563/clinexprheumatol/ 7k9ajj.
［33］	Karaa S, Cassius C, Jachiet M, et al. Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis［J］. Ann Dermatol Venereol, 2023,150（3）:243⁃245. doi: 10.1016/j.annder.2023.03.008.
［34］	Fischer K, Aringer M, Steininger J, et al. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib［J］. Br J Dermatol, 2022,187（3）:432⁃435. doi: 10.1111/bjd.21252.
［35］	Agud⁃Dios M, Arroyo⁃Andres J, Rubio⁃Muñiz C, et al. Juvenile dermatomyositis⁃associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy［J］. Dermatol Ther, 2022,35（12）:e15960. doi: 10.1111/dth.15960.
［36］	Delvino P, Bartoletti A, Monti S, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis［J］. Rheumatology （Oxford）, 2020,59（12）:4003. doi: 10.1093/rheumatology/keaa377.
［37］	中国医疗保健国际交流促进会皮肤科分会, 国家皮肤与免疫疾病临床医学研究中心. 成人皮肌炎诊疗中国专家共识（2022年）［J］. 中华皮肤科杂志, 2022,55（11）:939⁃948. doi: 10.35541/cjd.20220420.
［38］	Motamed⁃Sanaye A, Khazaee YF, Shokrgozar M, et al. JAK inhibitors in lichen planus: a review of pathogenesis and treatments［J］. J Dermatolog Treat, 2022,33（8）:3098⁃3103. doi: 10.1080/09546634.2022.2116926.
［39］	Moussa A, Colla T, Morrison B, et al. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib［J］. Australas J Dermatol, 2022,63（2）:276⁃277. doi: 10.1111/ajd.13811.
［40］	Moussa A, Colla TG, Asfour L, et al. Effective treatment of refractory lichen planus pemphigoides with a Janus kinase⁃1/2 inhibitor［J］. Clin Exp Dermatol, 2022,47（11）:2040⁃2041. doi: 10.1111/ced.15344.
［41］	Shao S, Tsoi LC, Sarkar MK, et al. IFN⁃γ enhances cell⁃mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus［J］. Sci Transl Med, 2019,11（511）:eaav7561. doi: 10. 1126/scitranslmed.aav7561.
［42］	Abduelmula A, Bagit A, Mufti A, et al. The use of Janus kinase inhibitors for lichen planus: an evidence⁃based review［J］. J Cutan Med Surg, 2023,27（3）:271⁃276. doi: 10.1177/1203475 4231156100.
［43］	Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune⁃mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement［J］. Ann Rheum Dis, 2021,80（1）:71⁃87. doi: 10.1136/annrheumdis⁃2020⁃21 8398.

[1]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[2]	Sun Yuxin, Huo Siyi, Chen Jiayu, Xiong Heping, Zhu Mingfang. COVID-19-associated skin diseases: a cross-sectional survey in Changsha, China [J]. Chinese Journal of Dermatology, 2025, 58(5): 464-469.
[3]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[4]	Chinese Association of Rehabilitation Dermatology, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Clinical application of red, blue, and yellow light therapy in dermatology: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 209-215.
[5]	Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240247-e20240247.
[6]	Zhang Beilei, Song Xiuzu. Etiology and pathogenesis of sensitive scalp [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240301-e20240301.
[7]	Dong Yi, Yan Xin, Munire·Tayier, Zhang Xingqi. Application of machine learning in dermatology [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240290-e20240290.
[8]	Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Expert consensus on the treatment of dermatoses with targeted drugs （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(2): 99-125.
[9]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230772-e20230772.
[10]	Ai Fangting, Sun Zijun, Miao Guoying, Yao Chunxia. Role of calcium-sensing receptors in the pathophysiology of skin of the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 76-79.
[11]	Zhang Jiaqi, Wu Fan, Han Yuqing, Liu Qi, Pan Yao. Application of multi-photon microscopy in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(9): 857-862.
[12]	Hao Feng, Liu Guoyan. Application of optical coherence tomography in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(9): 853-857.
[13]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[14]	Zeng Yue, Shao Huihong, Lin Shiwen, Wen Rou, Zou Xianbiao. Application of a wearable teleconsultation device in diagnosis of common skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(9): 797-800.
[15]	Jing Ke, Li Suo, Feng Suying. Clinical and immunoserological characteristics of 26 cases of linear IgA bullous dermatosis: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(6): 503-509.

Clinical application of baricitinib in dermatology

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10